The Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) updated the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. For a comprehensive list of recent updates, please see What's New in the Guidelines. A summary of key updates is outlined below. 

Note: Bictegravir/lenacapavir (Bixlenvo) was approved by the U.S. Food and Drug Administration in August 2026. The Panel is reviewing the available information for a future update. 

Section Added to the Guidelines 

• Principles of Antiretroviral Therapy 

Sections Removed From the Guidelines 

• Drug–Drug Interactions Tables 24a through 25b (available in the Archived Guidelines) 

Sections With Key Updates 

• What to Start (including all subsections) 

• Optimizing Antiretroviral Therapy in the Setting of Viral Suppression 

• Interruption of Antiretroviral Therapy 

• Adolescents and Young Adults With HIV 

• Substance Use Disorders and HIV 

• Women With HIV 

• Hepatitis B Virus (HBV)/HIV Coinfection 

• Cost Considerations and Antiretroviral Therapy 

• Drug–Drug Interactions 

Sections With Minor Updates 

• Introduction 

• Baseline Evaluation 

• Laboratory Testing for Initial Assessment and Monitoring of People With HIV 

• Treatment Goals 

• Hepatitis C Virus/HIV Coinfection 

• Appendix A. Drug Characteristics Tables 

• Appendix B: Antiretroviral Dosing Recommendations in Adults With Renal or Hepatic Insufficiency 

These guidelines are published and updated by the Panel based on the availability of new key clinical evidence on the use of antiretroviral therapy among people with HIV. To view or download the guidelines, go to the Adult and Adolescent Antiretroviral Guidelines section of the Clinicalinfo website. The guidelines tables and recommendations can also be downloaded as separate PDF files. 

Clinicalinfo welcomes your feedback on the latest revisions to the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. Please send your comments with the subject line “​Adult and Adolescent Antiretroviral Guidelines​” to [email protected] by October 8.